Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.

Autor: Deodhar A; Oregon Health & Science University, Portland, OR, USA., Blauvelt A; Oregon Medical Research Center, Portland, OR, USA., Lebwohl M; Mount Sinai Hospital, New York, NY, USA., Feely M; Mount Sinai Hospital, New York, NY, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Mount Sinai West and Mount Sinai Morningside, New York, NY, USA., Kronbergs A; Eli Lilly and Company, Indianapolis, IN, USA., Eberhart N; Eli Lilly and Company, Indianapolis, IN, USA., Zhu D; Eli Lilly and Company, Indianapolis, IN, USA., Inman E; Eli Lilly and Company, Indianapolis, IN, USA., Grace E; Eli Lilly and Company, Indianapolis, IN, USA., Holzkaemper T; Eli Lilly and Company, Indianapolis, IN, USA., Rahman P; Memorial University of Newfoundland, St. John's, NL, Canada., Marzo-Ortega H; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds Institute for Rheumatic and Musculoskeletal Medicine, The University of Leeds, Leeds, UK., Papp KA; Probity Medical Research and Alliance Clinical Trials, Waterloo, ON, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada., Merola JF; The University of Texas Southwestern Medical Center, Dallas, TX, USA., Gottlieb AB; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Schwartzman S; 72Nd Street Medical Associates, Scarsdale, NY, USA. SSconsulting@72ndmed.com.

Publikováno v: Arthritis research & therapy [Arthritis Res Ther] 2024 Feb 12; Vol. 26 (1), pp. 49. Date of Electronic Publication: 2024 Feb 12.

Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.

Autor: Egeberg A; Department of Dermatology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Kristensen LE; The Parker Institute, University of Copenhagen & Bispebjerg University Hospital, Copenhagen, Denmark., Puig L; Department of Dermatology, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain., Rich P; Oregon Dermatology and Research Center, Portland, Oregon, USA., Smith SD; The Dermatology and Skin Cancer Centre, Sydney, New South Wales, Australia.; The Sydney Adventist Hospital Clinical School, ANU Medical School, ANU College of Health and Medicine, The Australian National University, Canberra, Australian Capital Territory, Australia., Garrelts A; Eli Lilly and Company, Indianapolis, Indiana, USA., See K; Eli Lilly and Company, Indianapolis, Indiana, USA., Holzkaemper T; Eli Lilly and Company, Indianapolis, Indiana, USA., Fotiou K; Eli Lilly and Company, Indianapolis, Indiana, USA., Schuster C; Eli Lilly and Company, Indianapolis, Indiana, USA.; Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Publikováno v: The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2263108. Date of Electronic Publication: 2023 Oct 02.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study

Autor: Taylor, P, Krogulec, M, Dudek, A, Dudler, J, Drescher, E, Cseuz, R, Kausiene, R, Andersone, D, Unikiene, D, Sanchez Burson, J, Blanco Alonso, R, Dvorak, Z, Ghizdavescu, A, Irto, I, Larsson, E, Bello, N, Barry, J, Durand, F, Holzkaemper, T, Otawa, S, De Bono, S, Keystone, E, Rubbert-Roth, A, Combe, B, De La Torre, I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::e4fd0bf810e9400e6dc1f5229676e6d9
https://doi.org/10.1093/rheumatology/kex061.001

POSA370 Healthcare Resource Use By European Patients Enrolled in RA-be-Real: A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease Modifying Therapies

Autor: Alten, R, Burmester, G, Matucci-Cerinic, M, Salmon, JH, Zaremba-Pechmann, L, Fakhouri, W, de La Torre, I, Herrera, M, Holzkämper, T, Fautrel, B

Publikováno v: In Value in Health January 2022 25(1) Supplement:S221-S221